{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:46:26Z","timestamp":1792813586182,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T00:00:00Z","timestamp":1534896000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T00:00:00Z","timestamp":1534896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK112042"],"award-info":[{"award-number":["R01DK112042"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00125-018-4654-7","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T16:18:22Z","timestamp":1532103502000},"page":"2079-2086","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":340,"title":["Development of SGLT1 and SGLT2 inhibitors"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6082-662X","authenticated-orcid":false,"given":"Timo","family":"Rieg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Vallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,22]]},"reference":[{"key":"4654_CR1","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/S0140-6736(16)00618-8","volume":"387","author":"NCD Risk Factor Collaboration","year":"2016","unstructured":"NCD Risk Factor Collaboration (2016) Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4\u00b74 million participants. Lancet 387:1513\u20131530","journal-title":"Lancet"},{"key":"4654_CR2","doi-asserted-by":"publisher","first-page":"442","DOI":"10.2337\/dc09-0749","volume":"33","author":"M Laakso","year":"2010","unstructured":"Laakso M (2010) Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care 33:442\u2013449","journal-title":"Diabetes Care"},{"key":"4654_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","volume":"60","author":"V Vallon","year":"2017","unstructured":"Vallon V, Thomson SC (2017) Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60:215\u2013225","journal-title":"Diabetologia"},{"key":"4654_CR4","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1517\/14728222.2016.1168808","volume":"20","author":"P Song","year":"2016","unstructured":"Song P, Onishi A, Koepsell H, Vallon V (2016) Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. Expert Opin Ther Targets 20:1109\u20131125","journal-title":"Expert Opin Ther Targets"},{"key":"4654_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/978-1-4684-7758-0_8","volume":"103","author":"VW Dennis","year":"1978","unstructured":"Dennis VW, Brazy PC (1978) Phosphate and glucose transport in the proximal convoluted tubule: mutual dependency on sodium. Adv Exp Med Biol 103:79\u201380","journal-title":"Adv Exp Med Biol"},{"key":"4654_CR6","doi-asserted-by":"publisher","first-page":"766","DOI":"10.2337\/diab.41.6.766","volume":"41","author":"SC Cramer","year":"1992","unstructured":"Cramer SC, Pardridge WM, Hirayama BA, Wright EM (1992) Colocalization of GLUT2 glucose transporter, sodium\/glucose cotransporter, and gamma-glutamyl transpeptidase in rat kidney with double-peroxidase immunocytochemistry. Diabetes 41:766\u2013770","journal-title":"Diabetes"},{"key":"4654_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2337\/db11-1029","volume":"61","author":"V Gorboulev","year":"2012","unstructured":"Gorboulev V, Schurmann A, Vallon V et al (2012) Na+-d-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61:187\u2013196","journal-title":"Diabetes"},{"key":"4654_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1681\/ASN.2010030246","volume":"22","author":"V Vallon","year":"2011","unstructured":"Vallon V, Platt KA, Cunard R et al (2011) SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22:104\u2013112","journal-title":"J Am Soc Nephrol"},{"key":"4654_CR9","doi-asserted-by":"publisher","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","volume":"306","author":"T Rieg","year":"2014","unstructured":"Rieg T, Masuda T, Gerasimova M et al (2014) Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Ren Physiol 306:F188\u2013F193","journal-title":"Am J Physiol Ren Physiol"},{"key":"4654_CR10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/j.0954-6820.1927.tb18538.x","volume":"67","author":"U Hjarne","year":"1927","unstructured":"Hjarne U (1927) A study of orthoglycaemic glycosuria with particular reference to its hereditability. Acta Med Scand 67:495\u2013571","journal-title":"Acta Med Scand"},{"key":"4654_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2215\/CJN.04010609","volume":"5","author":"R Santer","year":"2010","unstructured":"Santer R, Calado J (2010) Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 5:133\u2013141","journal-title":"Clin J Am Soc Nephrol"},{"key":"4654_CR12","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1152\/physrev.00055.2009","volume":"91","author":"EM Wright","year":"2011","unstructured":"Wright EM, Loo DD, Hirayama BA (2011) Biology of human sodium glucose transporters. Physiol Rev 91:733\u2013794","journal-title":"Physiol Rev"},{"key":"4654_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1172\/JCI10963","volume":"107","author":"SC Thomson","year":"2001","unstructured":"Thomson SC, Deng A, Bao D, Satriano J, Blantz RC, Vallon V (2001) Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes. J Clin Invest 107:217\u2013224","journal-title":"J Clin Invest"},{"key":"4654_CR14","doi-asserted-by":"publisher","first-page":"F156","DOI":"10.1152\/ajprenal.00409.2012","volume":"304","author":"V Vallon","year":"2013","unstructured":"Vallon V, Rose M, Gerasimova M et al (2013) Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Ren Physiol 304:F156\u2013F167","journal-title":"Am J Physiol Ren Physiol"},{"key":"4654_CR15","doi-asserted-by":"publisher","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","volume":"306","author":"V Vallon","year":"2014","unstructured":"Vallon V, Gerasimova M, Rose MA et al (2014) SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Ren Physiol 306:F194\u2013F204","journal-title":"Am J Physiol Ren Physiol"},{"key":"4654_CR16","doi-asserted-by":"publisher","first-page":"12018","DOI":"10.1074\/jbc.C117.794982","volume":"292","author":"XX Wang","year":"2017","unstructured":"Wang XX, Luo Y, Wang D et al (2017) A dual agonist of farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice. J Biol Chem 292:12018\u201312024","journal-title":"J Biol Chem"},{"key":"4654_CR17","doi-asserted-by":"publisher","first-page":"316","DOI":"10.2337\/dc14-0920","volume":"38","author":"K Khunti","year":"2015","unstructured":"Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK (2015) Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care 38:316\u2013322","journal-title":"Diabetes Care"},{"key":"4654_CR18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323\u2013334","journal-title":"N Engl J Med"},{"key":"4654_CR19","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, Cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128","journal-title":"N Engl J Med"},{"key":"4654_CR20","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644\u2013657","journal-title":"N Engl J Med"},{"key":"4654_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/1479164114559852","volume":"12","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Zinman B, Wanner C et al (2015) SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 12:90\u2013100","journal-title":"Diab Vasc Dis Res"},{"key":"4654_CR22","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1681\/ASN.V10122569","volume":"10","author":"V Vallon","year":"1999","unstructured":"Vallon V, Richter K, Blantz RC, Thomson S, Osswald H (1999) Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 10:2569\u20132576","journal-title":"J Am Soc Nephrol"},{"key":"4654_CR23","first-page":"R75","volume":"302","author":"SC Thomson","year":"2012","unstructured":"Thomson SC, Rieg T, Miracle C et al (2012) Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Phys Regul Integr Comp Phys 302:R75\u2013R83","journal-title":"Am J Phys Regul Integr Comp Phys"},{"key":"4654_CR24","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","volume":"2","author":"AH Barnett","year":"2014","unstructured":"Barnett AH, Mithal A, Manassie J et al (2014) Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2:369\u2013384","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4654_CR25","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/ki.2011.79","volume":"80","author":"FA Holtkamp","year":"2011","unstructured":"Holtkamp FA, de Zeeuw D, Thomas MC et al (2011) An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 80:282\u2013287","journal-title":"Kidney Int"},{"key":"4654_CR26","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/dom.13057","volume":"20","author":"S Petrykiv","year":"2018","unstructured":"Petrykiv S, Laverman GD, de Zeeuw D, Heerspink HJL (2018) Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition? Diabetes Obes Metab 20:224\u2013227","journal-title":"Diabetes Obes Metab"},{"key":"4654_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/MNH.0000000000000084","volume":"24","author":"M Skrtic","year":"2015","unstructured":"Skrtic M, Cherney DZ (2015) Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens 24:96\u2013103","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"4654_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","volume":"137","author":"C Wanner","year":"2018","unstructured":"Wanner C, Lachin JM, Inzucchi SE et al (2018) Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 137:119\u2013129","journal-title":"Circulation"},{"key":"4654_CR29","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2215\/CJN.10180916","volume":"12","author":"S Petrykiv","year":"2017","unstructured":"Petrykiv S, Sjostrom CD, Greasley PJ, Xu J, Persson F, Heerspink HJL (2017) Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function. Clin J Am Soc Nephrol 12:751\u2013759","journal-title":"Clin J Am Soc Nephrol"},{"key":"4654_CR30","doi-asserted-by":"publisher","unstructured":"Layton AT, Vallon V (2018) SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism. Am J Physiol Ren Physiol https:\/\/doi.org\/10.1152\/ajprenal.00551.2017","DOI":"10.1152\/ajprenal.00551.2017"},{"key":"4654_CR31","doi-asserted-by":"publisher","first-page":"F1269","DOI":"10.1152\/ajprenal.00543.2015","volume":"310","author":"AT Layton","year":"2016","unstructured":"Layton AT, Vallon V, Edwards A (2016) Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron. Am J Physiol Ren Physiol 310:F1269\u2013F1283","journal-title":"Am J Physiol Ren Physiol"},{"key":"4654_CR32","doi-asserted-by":"publisher","first-page":"F1343","DOI":"10.1152\/ajprenal.00007.2015","volume":"308","author":"AT Layton","year":"2015","unstructured":"Layton AT, Vallon V, Edwards A (2015) Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition. Am J Physiol Ren Physiol 308:F1343\u2013F1357","journal-title":"Am J Physiol Ren Physiol"},{"key":"4654_CR33","doi-asserted-by":"publisher","first-page":"F227","DOI":"10.1152\/ajprenal.00689.2014","volume":"309","author":"J O\u2019Neill","year":"2015","unstructured":"O\u2019Neill J, Fasching A, Pihl L, Patinha D, Franzen S, Palm F (2015) Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Ren Physiol 309:F227\u2013F234","journal-title":"Am J Physiol Ren Physiol"},{"key":"4654_CR34","doi-asserted-by":"publisher","first-page":"844","DOI":"10.14740\/jocmr2760w","volume":"8","author":"M Sano","year":"2016","unstructured":"Sano M, Takei M, Shiraishi Y, Suzuki Y (2016) Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res 8:844\u2013847","journal-title":"J Clin Med Res"},{"key":"4654_CR35","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2337\/dc17-1096","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, Zinman B, Fitchett D et al (2018) How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care 41:356\u2013363","journal-title":"Diabetes Care"},{"key":"4654_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2337\/diabetes.54.1.1","volume":"54","author":"A Ceriello","year":"2005","unstructured":"Ceriello A (2005) Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 54:1\u20137","journal-title":"Diabetes"},{"key":"4654_CR37","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/350354a0","volume":"350","author":"E Turk","year":"1991","unstructured":"Turk E, Zabel B, Mundlos S, Dyer J, Wright EM (1991) Glucose\/galactose malabsorption caused by a defect in the Na+\/glucose cotransporter. Nature 350:354\u2013356","journal-title":"Nature"},{"key":"4654_CR38","doi-asserted-by":"publisher","first-page":"E1358","DOI":"10.1152\/ajpendo.00412.2009","volume":"297","author":"R Moriya","year":"2009","unstructured":"Moriya R, Shirakura T, Ito J, Mashiko S, Seo T (2009) Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice. Am J Physiol Endocrinol Metab 297:E1358\u2013E1365","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"4654_CR39","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/0006-291X(91)92053-M","volume":"181","author":"K Miyamoto","year":"1991","unstructured":"Miyamoto K, Hase K, Taketani Y et al (1991) Diabetes and glucose transporter gene expression in rat small intestine. Biochem Biophys Res Commun 181:1110\u20131117","journal-title":"Biochem Biophys Res Commun"},{"key":"4654_CR40","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1530\/JOE-14-0161","volume":"222","author":"H Ogata","year":"2014","unstructured":"Ogata H, Seino Y, Harada N et al (2014) KATP channel as well as SGLT1 participates in GIP secretion in the diabetic state. J Endocrinol 222:191\u2013200","journal-title":"J Endocrinol"},{"key":"4654_CR41","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","volume":"14","author":"R Grempler","year":"2012","unstructured":"Grempler R, Thomas L, Eckhardt M et al (2012) Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14:83\u201390","journal-title":"Diabetes Obes Metab"},{"key":"4654_CR42","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s001250051092","volume":"41","author":"Y Fujita","year":"1998","unstructured":"Fujita Y, Kojima H, Hidaka H, Fujimiya M, Kashiwagi A, Kikkawa R (1998) Increased intestinal glucose absorption and postprandial hyperglycaemia at the early step of glucose intolerance in Otsuka Long-Evans Tokushima Fatty Rats. Diabetologia 41:1459\u20131466","journal-title":"Diabetologia"},{"key":"4654_CR43","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/labinvest.2015.129","volume":"96","author":"JA Dominguez Rieg","year":"2016","unstructured":"Dominguez Rieg JA, Chirasani VR, Koepsell H, Senapati S, Mahata SK, Rieg T (2016) Regulation of intestinal SGLT1 by catestatin in hyperleptinemic type 2 diabetic mice. Lab Investig 96:98\u2013111","journal-title":"Lab Investig"},{"key":"4654_CR44","doi-asserted-by":"publisher","first-page":"e89977","DOI":"10.1371\/journal.pone.0089977","volume":"9","author":"PV Roder","year":"2014","unstructured":"Roder PV, Geillinger KE, Zietek TS, Thorens B, Koepsell H, Daniel H (2014) The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing. PLoS One 9:e89977","journal-title":"PLoS One"},{"key":"4654_CR45","doi-asserted-by":"publisher","first-page":"G946","DOI":"10.1152\/ajpgi.00286.2014","volume":"308","author":"RL Dobbins","year":"2015","unstructured":"Dobbins RL, Greenway FL, Chen L et al (2015) Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release. Am J Physiol Gastrointest Liver Physiol 308:G946\u2013G954","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"Suppl 3","key":"4654_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1463-1326.2009.01073.x","volume":"11","author":"T Vilsboll","year":"2009","unstructured":"Vilsboll T (2009) The effects of glucagon-like peptide-1 on the beta cell. Diabetes Obes Metab 11(Suppl 3):11\u201318","journal-title":"Diabetes Obes Metab"},{"key":"4654_CR47","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696\u20131705","journal-title":"Lancet"},{"key":"4654_CR48","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1021\/acs.jmedchem.6b01541","volume":"60","author":"NC Goodwin","year":"2017","unstructured":"Goodwin NC, Ding ZM, Harrison BA et al (2017) Discovery of LX2761, a sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor restricted to the intestinal lumen, for the treatment of diabetes. J Med Chem 60:710\u2013721","journal-title":"J Med Chem"},{"key":"4654_CR49","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1124\/jpet.113.203364","volume":"345","author":"DR Powell","year":"2013","unstructured":"Powell DR, Smith M, Greer J et al (2013) LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium\/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther 345:250\u2013259","journal-title":"J Pharmacol Exp Ther"},{"key":"4654_CR50","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/clpt.2012.58","volume":"92","author":"B Zambrowicz","year":"2012","unstructured":"Zambrowicz B, Freiman J, Brown PM et al (2012) LX4211, a dual SGLT1\/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 92:158\u2013169","journal-title":"Clin Pharmacol Ther"},{"key":"4654_CR51","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1172\/JCI100559","volume":"12","author":"H Chasis","year":"1933","unstructured":"Chasis H, Jolliffe N, Smith HW (1933) The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man. J Clin Invest 12:1083\u20131090","journal-title":"J Clin Invest"},{"key":"4654_CR52","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1172\/JCI112981","volume":"79","author":"L Rossetti","year":"1987","unstructured":"Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA (1987) Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 79:1510\u20131515","journal-title":"J Clin Invest"},{"key":"4654_CR53","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1172\/JCI113157","volume":"80","author":"L Rossetti","year":"1987","unstructured":"Rossetti L, Shulman GI, Zawalich W, DeFronzo RA (1987) Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 80:1037\u20131044","journal-title":"J Clin Invest"},{"key":"4654_CR54","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.2337\/diabetes.48.9.1794","volume":"48","author":"A Oku","year":"1999","unstructured":"Oku A, Ueta K, Arakawa K et al (1999) T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 48:1794\u20131800","journal-title":"Diabetes"},{"key":"4654_CR55","doi-asserted-by":"publisher","first-page":"E1136","DOI":"10.3390\/molecules21091136","volume":"21","author":"CI Choi","year":"2016","unstructured":"Choi CI (2016) Sodium-glucose cotransporter 2 (SGLT2) Inhibitors from natural products: discovery of next-generation antihyperglycemic agents. Molecules 21:E1136","journal-title":"Molecules"},{"key":"4654_CR56","doi-asserted-by":"crossref","unstructured":"Isaji M (2011) SGLT2 inhibitors: molecular design and potential differences in effect. Kidney Int 79 (Suppl 120): S14\u2013S19","DOI":"10.1038\/ki.2010.511"},{"key":"4654_CR57","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1177\/1479164114563304","volume":"12","author":"P Lapuerta","year":"2015","unstructured":"Lapuerta P, Zambrowicz B, Strumph P, Sands A (2015) Development of sotagliflozin, a dual sodium-dependent glucose transporter 1\/2 inhibitor. Diab Vasc Dis Res 12:101\u2013110","journal-title":"Diab Vasc Dis Res"},{"key":"4654_CR58","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejphar.2017.04.010","volume":"806","author":"T Inoue","year":"2017","unstructured":"Inoue T, Takemura M, Fushimi N et al (2017) Mizagliflozin, a novel selective SGLT1 inhibitor, exhibits potential in the amelioration of chronic constipation. Eur J Pharmacol 806:25\u201331","journal-title":"Eur J Pharmacol"},{"key":"4654_CR59","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/clpt.2008.251","volume":"85","author":"B Komoroski","year":"2009","unstructured":"Komoroski B, Vachharajani N, Boulton D et al (2009) Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 85:520\u2013526","journal-title":"Clin Pharmacol Ther"},{"key":"4654_CR60","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/dom.12073","volume":"15","author":"T Heise","year":"2013","unstructured":"Heise T, Seewaldt-Becker E, Macha S et al (2013) Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks\u2019 treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 15:613\u2013621","journal-title":"Diabetes Obes Metab"},{"key":"4654_CR61","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1463-1326.2011.01406.x","volume":"13","author":"S Sha","year":"2011","unstructured":"Sha S, Devineni D, Ghosh A et al (2011) Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 13:669\u2013672","journal-title":"Diabetes Obes Metab"},{"key":"4654_CR62","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/1479164114561992","volume":"12","author":"LA Gallo","year":"2015","unstructured":"Gallo LA, Wright EM, Vallon V (2015) Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res 12:78\u201389","journal-title":"Diab Vasc Dis Res"},{"key":"4654_CR63","doi-asserted-by":"publisher","first-page":"E117","DOI":"10.1152\/ajpendo.00439.2012","volume":"304","author":"DR Powell","year":"2013","unstructured":"Powell DR, DaCosta CM, Gay J et al (2013) Improved glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrinol Metab 304:E117\u2013E130","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"4654_CR64","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.2337\/dc14-2806","volume":"38","author":"AT Sands","year":"2015","unstructured":"Sands AT, Zambrowicz BP, Rosenstock J et al (2015) Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 38:1181\u20131188","journal-title":"Diabetes Care"},{"key":"4654_CR65","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","volume":"377","author":"SK Garg","year":"2017","unstructured":"Garg SK, Henry RR, Banks P et al (2017) Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 377:2337\u20132348","journal-title":"N Engl J Med"},{"key":"4654_CR66","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/S2213-8587(17)30308-X","volume":"5","author":"P Dandona","year":"2017","unstructured":"Dandona P, Mathieu C, Phillip M et al (2017) Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 5:864\u2013876","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4654_CR67","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.2337\/dc15-1730","volume":"38","author":"RR Henry","year":"2015","unstructured":"Henry RR, Thakkar P, Tong C, Polidori D, Alba M (2015) Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care 38:2258\u20132265","journal-title":"Diabetes Care"},{"key":"4654_CR68","doi-asserted-by":"crossref","unstructured":"Fattah H, Vallon V (2018) The potential role of SGLT2 inhibitors in the treatment of type 1 diabetes. Drugs 78:717\u2013726","DOI":"10.1007\/s40265-018-0901-y"},{"key":"4654_CR69","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/dom.12494","volume":"17","author":"TR Pieber","year":"2015","unstructured":"Pieber TR, Famulla S, Eilbracht J et al (2015) Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab 17:928\u2013935","journal-title":"Diabetes Obes Metab"},{"key":"4654_CR70","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1681\/ASN.2016030278","volume":"28","author":"HJ Heerspink","year":"2017","unstructured":"Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V (2017) Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 28:368\u2013375","journal-title":"J Am Soc Nephrol"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-018-4654-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-018-4654-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-018-4654-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T20:26:39Z","timestamp":1661631999000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-018-4654-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,22]]},"references-count":70,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["4654"],"URL":"https:\/\/doi.org\/10.1007\/s00125-018-4654-7","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,22]]},"assertion":[{"value":"15 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Over the past 36\u00a0months, VV has served as a consultant and received honoraria from Bayer, Boehringer Ingelheim, Intarcia Therapeutics, Astra-Zeneca, Janssen Pharmaceutical, Eli Lilly and Merck, and received grant support for investigator-initiated research from Astra-Zeneca, Bayer, Boehringer Ingelheim, Fresenius and Janssen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Duality of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}